Current management tactics for patients with dementia

Current management tactics for patients with dementia

Dementia develops as a result of continuous long-term progression of less severe cognitive impairment (CI). Social and psychological methods (neurocognitive stimulation and neurocognitive training) are the mainstay of treatment for dementia. At the moment, there are no drugs both to cure dementia an...

Full description

Bibliographic Details
Main Authors:	A. V. Medvedeva, O. V. Kosivtsova, K. A. Makhinov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2018-06-01
Series:	Неврология, нейропсихиатрия, психосоматика
Subjects:	dementia alzheimer's disease anticholinesterase drugs nmda receptor antagonists
Online Access:	https://nnp.ima-press.net/nnp/article/view/893

Similar Items

The use of angiotensin receptor blockers in dementia prevention
by: Jordana de Araujo Müller, et al.
Published: (2023-09-01)

Attenuation of Vanadium-Induced Neurotoxicity in Rat Hippocampal Slices (In Vitro) and Mice (In Vivo) by ZA-II-05, a Novel NMDA-Receptor Antagonist
by: Amany Digal Ladagu, et al.
Published: (2023-11-01)

An Overview of the Involvement of D-Serine in Cognitive Impairment in Normal Aging and Dementia
by: Magdalena Orzylowski, et al.
Published: (2021-10-01)

NMDA receptor antagonists in the treatment of patients with vascular cognitive imprairments
by: I.S. Preobrazhenskaya
Published: (2014-10-01)

Current Evidence of Chinese Herbal Constituents with Effects on NMDA Receptor Blockade
by: David T. Yew, et al.
Published: (2013-08-01)

Some aspects of medication and non-medication treatment of Alzheimer's disease
by: O. V. Kotova, et al.
Published: (2015-12-01)

Dementia patients have greater anti-cholinergic drug burden on discharge from hospital: A multicentre cross-sectional study
by: J. Randall, et al.
Published: (2021-04-01)

Cognitive and motor training for patients with moderate cognitive impairment and mild dementia
by: A. A. Naumenko, et al.
Published: (2018-12-01)

Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy
by: Vladimir D. Dergachev, et al.
Published: (2023-03-01)

Use of Riluzole for the Treatment of Hereditary Ataxias: A Systematic Review
by: Iván Nicolas Ayala, et al.
Published: (2022-08-01)

NMDA receptor antagonists as potential therapy in cerebellar degenerative disorders
by: Olga S. Belozor, et al.
Published: (2022-06-01)

Glutamate Receptor Dysregulation and Platelet Glutamate Dynamics in Alzheimer’s and Parkinson’s Diseases: Insights into Current Medications
by: Deepa Gautam, et al.
Published: (2023-11-01)

Primary headaches and cognitive disorders — pathophysiologically associated and comorbidity conditions.
by: D. A. Iskra, et al.
Published: (2018-11-01)

Management of moderate to severe Alzheimer’s disease: Focus on memantine
by: Evangelyn Dominguez, et al.
Published: (2011-12-01)

Lamiaceae Family Plants as a Potential Anticholinesterase Source in the Treatment of Alzheimer’s Disease
by: Gulacti TOPCU, et al.
Published: (2014-03-01)

Treatment of Cerebral Ischemia Through NMDA Receptors: Metabotropic Signaling and Future Directions
by: Yuanyuan Li, et al.
Published: (2022-02-01)

The possibilities of using xenon therapy in patients with severe cancer pain
by: R. R. Sarmanayeva, et al.
Published: (2020-07-01)

Targeting NMDA Receptor Complex in Management of Epilepsy
by: Shravan Sivakumar, et al.
Published: (2022-10-01)

Antiparkinsonian activity of new N-methyl-D-aspartate receptor ligands in the arecoline hyperkinesis test
by: V. D. Dergachev, et al.
Published: (2021-09-01)

The effect of memantine on behavioural sensitisation to methamphetamine in mice
by: L. Landa, et al.
Published: (2012-10-01)

The effect of felbamate on behavioural sensitization to methamphetamine in mice
by: L. Landa, et al.
Published: (2012-07-01)

Cognitive impairment and dementia
by: V. A. Parfenov, et al.
Published: (2018-11-01)

Cognitive enhancing effects and anticholinesterase activity of stem bark and leaf extracts of Prunus africana
by: David N. Ngai, et al.
Published: (2022-12-01)

Dementia : An overview
by: S Rohatgi
Published: (2013-01-01)

Cognitive impairment in hospitalized patients with COVID-19
by: S. P. Bordovsky, et al.
Published: (2022-03-01)

Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists
by: Nuno A. L. Pereira, et al.
Published: (2016-08-01)

NMDAR-dependent somatic potentiation of synaptic inputs is correlated with β amyloid-mediated neuronal hyperactivity
by: Yifei Bao, et al.
Published: (2021-09-01)

Dementia of the Alzheimer type: current state of the problem
by: N.A. Tyuvina, et al.
Published: (2014-05-01)

Effects of neonatal NMDA-subtype glutamate receptor blockade on behavior of adult male rats
by: I. M. Sukhanov, et al.
Published: (2022-11-01)

Aging and pain: Specific features of neuropathy treatment in the elderly
by: A N Barinov, et al.
Published: (2014-12-01)

NMDA receptor antagonists attenuate intrathecal morphine-induced pruritus through ERK phosphorylation
by: Le Shen, et al.
Published: (2018-06-01)

Gender differences in Parkinson's disease with dementia and dementia with Lewy bodies
by: Lidadi L. Agbomi, et al.
Published: (2022-12-01)

Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis
by: Yannick Nicolas Gerber, et al.
Published: (2013-12-01)

Ketamine exacerbates cortical neuroapoptosis under hyperoxic conditions by upregulating expression of the N-methyl-D-aspartate receptor subunit NR1 in the developing rat brain
by: Changyi Wu, et al.
Published: (2018-05-01)

The role of Memantine in slowing cognitive decline in patients with Down syndrome–A systematic review and meta analysis
by: Zarmina Islam, et al.
Published: (2024-03-01)

The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer’s Disease-like Pathology
by: Dariusz Świetlik, et al.
Published: (2022-03-01)

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, in Silico Trials
by: Dariusz Świetlik, et al.
Published: (2022-04-01)

Vascular dementia: current concepts and nomenclature harmonization
by: Lea Tenenholz Grinberg

Severe dementia: A review on diagnoses, therapeutic management and ethical issues
by: Lilian Schafirovits-Morillo, et al.

Cognitive impairment in patients with coronavirus infection
by: Y. A. Starchina, et al.
Published: (2022-08-01)